Open AccessRandomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group
Author(s) -
Leo Mascarenhas,
Yueh Yun,
Pooja Hingorani,
James R. Anderson,
Elizabeth Lyden,
David A. Rodeberg,
Daniel J. Indelicato,
Simon C. Kao,
Roshni Dasgupta,
Sheri L. Spunt,
William H. Meyer,
Douglas S. Hawkins
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.00576
Subject(s) - temsirolimus , medicine , bevacizumab , clinical endpoint , interim analysis , oncology , surgery , chemotherapy , randomized controlled trial , discovery and development of mtor inhibitors , apoptosis , biochemistry , chemistry , protein kinase b
The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus for additional investigation in rhabdomyosarcoma (RMS) when administered in combination with cytotoxic chemotherapy to patients with RMS in first relapse with unfavorable prognosis.